European stocks closed lower on Wednesday as traders paused for breath after a strong "risk-on" rally since the Donald Trump's election win.
Robert Kindler, Morgan Stanley Vice Chairman and Global Head of M&A, discusses the current environment for mergers and acquisitions as well as what to expect from the likes of the Bayer/Monsanto deal or a potential Saleforce/Twitter deal.
Monsanto reported a surprise adjusted profit, helped by a drop in expenses and higher corn seed volumes.
European stocks closed just above the flatline as investors awaited the outcomes of policy meetings by the U.S. Federal Reserve and Bank of Japan.
U.S. stock-index futures gained on Tuesday as traders awaited the start of the U.S. Federal Reserve's two-day meeting.
Alliance for Bio-Integrity's Steven Druker says the big concern from the merger is the lack of rigorous testing needed for genetically-modified foods.
European stocks ended mostly mixed on Wednesday, as a renewed decline in oil prices put a dampener on sentiment.
Bayer has won over Monsanto with a takeover offer of around $66 billion, ending months of wrangling after increasing its bid for a third time.
Jeremy Redenius, equity analyst for European chemicals at Bernstein, says a merger deal only has a 50 percent chance of getting regulatory approval.
Chemicals group poised to announce deal to buy U.S. seeds company Monsanto for more than $66 billion, people familiar with the matter told Reuters.
Agrium and Potash Corp of Saskatchewan said they would combine to create a fertilizer and farm retailing giant with proforma enterprise value of $36 billion.
Bayer is close to a deal to acquire Monsanto, and an announcement could come as early as late next week, sources told CNBC Friday.
European stocks closed higher on Wednesday, despite weak German industrial production numbers and as investors awaited economic data from the U.S.
European stocks seesawed in trade on Tuesday as oil prices slipped and poor U.S. service sector data pushed many markets down.
German drugmaker Bayer and Monsanto are closing in on a deal, with Monsanto telling Bayer that it is "close" on price, sources told CNBC Tuesday.
In light of the M&A news surrounding Monsanto and Bayer, Mark Phelps, CIO of concentrated global equities at Alliance Bernstein, explains why more mergers are on the horizon.
The German pharmaceutical group raised its takeover approach to Monsanto to $127.50 per share on Sept. 6. It may even go further, says BreakingViews.
CNBC and NBC NY found thousands of FDA safety reports where deaths were classified as less serious injuries and equipment malfunctions.
Allen & Co. represents Wal-Mart in the latest sign that smaller upstarts are challenging the big banks on merger deals.
Bayer surpassed second-quarter earnings expectations and raised its guidance for the year on strong gains in stroke prevention pill Xarelto.